Portfolio Lab

West Pharmaceutical Services Inc

  • Stock
  • Ticker WST
  • ISIN US9553061055
  • NYSE

Health care · Medical technology · USA

$390.30 −1.61%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of West Pharmaceutical Services Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

WSTGlobal equities (VT)

$10,000 grew to $50,380. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −59.3% in 04/2025, measured from the peak in 12/2021. The old peak has not been reached again yet.

1-year return
+52.0%
5-year return p.a.
−2.5%
10-year return p.a.
+17.6%
Volatility p.a.
30.6%
Largest decline
−59.3%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue749698767805805845872875
Gross profit274232274294304296329347
Operating income160107154168157177179267
EBITDA200147195211204222225313
Net income13090132140132139154214
Earnings per share1.781.231.821.921.821.922.153.02
Balance sheet
Total assets3,6433,6183,9534,1064,2704,1104,0764,061
Liabilities9619351,0241,0541,0941,1191,0861,093
Equity2,6822,6832,9293,0523,1762,9902,9902,968
Cash485404510629791521436464
Long-term debt203203203203203203203203
Cash flow
Operating cash flow19012917719725190124190
Capital expenditure-105-71-75-63-76-43-43-39
Free cash flow85581021341754781150

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +89.1%, weakest 2022 at −49.7%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026$3.02
23 Jul 2026$2.15
23 Apr 2026$1.92
17 Feb 2026$1.82
23 Oct 2025$1.92
24 Jul 2025$1.82
24 Apr 2025$1.23
18 Feb 2025$1.78
24 Oct 2024$1.85
25 Jul 2024$1.51
25 Apr 2024$1.55
20 Feb 2024$1.83

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€25bn
Market cap in trading currency
$27.2bn
Enterprise value
$26.9bn
P/E
43.8
P/S
8.00
P/B
9.16
EV/Sales
7.93
EV/EBITDA
27.9
Earnings yield
2.3%
FCF yield
1.7%

Results (last four quarters)

Revenue
$3.40bn
Gross profit
$1.28bn
EBITDA
$965m
Net income
$639m
Earnings per share
$8.91
Revenue per share
$48.76
Revenue growth
+8.7%
Earnings growth
+52.9%

Profitability

Gross margin
37.6%
Operating margin
23.0%
Net margin
18.8%
Return on equity
21.2%
Return on assets
15.7%

Balance sheet and cash flow

Cash
$464m
Cash per share
$6.66
Financial debt
$203m
Debt/equity %
7
Current ratio
2.82
Book value per share
$42.61
Operating cash flow
$655m
Free cash flow
$453m

Dividend

Dividend yield
0.30%
Dividend (12 months)
$1.18
Yield (12 months)
0.30%
Payout ratio
13%
Ex-dividend date
11 Nov 2026

Shares and trading

Shares outstanding
69.7m
Volume
595,074
Avg. volume 3 months
610,443
Relative volume
1.0

Price and technicals

Price
$390.30
1 day
−1.6%
52-week high
$417.80
52-week low
$230.95
Distance to 52-week high
−6.6%
Distance to 52-week low
+69.0%
Distance to 50-day line
+1.0%
Distance to 200-day line
+19.8%
RSI (14)
43
Volatility 1M
27.8%

Performance

1 week
−6.3%
1 month
−0.9%
3 months
+10.5%
6 months
+23.3%
YTD
+41.9%
1 year
+51.3%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has WST performed since 11/2016?

$10,000 grew to $50,380 by 20 Nov 2026, which is +17.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is WST?

Volatility was 30.6% per year, measured on monthly returns. The largest decline from a peak was −59.3%, with the low in 04/2025.

How does WST compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, WST returned +17.6% at 30.6%. The correlation of monthly returns was 0.48; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

West Pharmaceutical Services Inc (WST): Return and risk